Mirabegron Ratiopharm (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation relaxes the muscle during the filling phase, increasing bladder capacity and decreasing involuntary contractions that cause urgency and leakage.

The specific dose of mirabegron is determined by the prescribing clinician based on the patient’s medical condition, renal function, and concomitant medications. The prescriber will select the appropriate strength and dosing schedule for each individual.

Safety data for mirabegron in pregnancy and lactation are limited, and the medication is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron offers a non‑anticholinergic option, which can be advantageous for patients who experience dry mouth, constipation or cognitive effects with antimuscarinics. Both classes improve bladder storage symptoms, but mirabegron may be preferred when anticholinergic side effects are a concern or when combination therapy is needed.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from excess moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Mirabegron Ratiopharm is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include significant hypertension, acute urinary retention that may require catheterisation, angioedema, and rare cardiac events such as myocardial infarction. Patients should promptly report severe headache, chest pain, sudden swelling of the face or throat, or inability to urinate.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with bladder outlet obstruction or those taking strong CYP2D6 inhibitors.